Stock Research for JAZZ

JAZZ

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

JAZZ Stock Chart & Research Data

The JAZZ chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the JAZZ chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


JAZZ Due diligence Resources & Stock Charts

The JAZZ stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View JAZZ Detailed Price Forecast - CNN Money CNN View JAZZ Detailed Summary - Google Finance
Yahoo View JAZZ Detailed Summary - Yahoo! Finance Zacks View JAZZ Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View JAZZ Trends & Analysis - Trade-Ideas Barrons View JAZZ Major Holders - Barrons
NASDAQ View JAZZ Call Transcripts - NASDAQ Seeking View JAZZ Breaking News & Analysis - Seeking Alpha
Spotlight View JAZZ Annual Report - CompanySpotlight.com OTC Report View JAZZ OTC Short Report - OTCShortReport.com
TradeKing View JAZZ Fundamentals - TradeKing Charts View JAZZ SEC Filings - Bar Chart
WSJ View Historical Prices for JAZZ - The WSJ Morningstar View Performance/Total Return for JAZZ - Morningstar
MarketWatch View the Analyst Estimates for JAZZ - MarketWatch CNBC View the Earnings History for JAZZ - CNBC
StockMarketWatch View the JAZZ Earnings - StockMarketWatch MacroAxis View JAZZ Buy or Sell Recommendations - MacroAxis
Bullish View the JAZZ Bullish Patterns - American Bulls Short Pains View JAZZ Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View JAZZ Stock Mentions - StockTwits PennyStocks View JAZZ Stock Mentions - PennyStockTweets
Twitter View JAZZ Stock Mentions - Twitter Invest Hub View JAZZ Investment Forum News - Investor Hub
Yahoo View JAZZ Stock Mentions - Yahoo! Message Board Seeking Alpha View JAZZ Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for JAZZ - SECform4.com Insider Cow View Insider Transactions for JAZZ - Insider Cow
CNBC View JAZZ Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for JAZZ - OTC Markets
Yahoo View Insider Transactions for JAZZ - Yahoo! Finance NASDAQ View Institutional Holdings for JAZZ - NASDAQ


Stock Charts

FinViz View JAZZ Stock Insight & Charts - FinViz.com StockCharts View JAZZ Investment Charts - StockCharts.com
BarChart View JAZZ Stock Overview & Charts - BarChart Trading View View JAZZ User Generated Charts - Trading View


Latest Financial News for JAZZ

Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018
Posted on Tuesday April 24, 2018

DUBLIN , April 24, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 first quarter financial results on Tuesday, May 8, 2018 , after the close of ...


Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
Posted on Thursday April 19, 2018

Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.


Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
Posted on Thursday April 19, 2018

In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.


Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
Posted on Wednesday April 18, 2018

In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.


Enter a stock symbol to view the stock details.